Repository logo
 
Publication

Epigenetic and Drug Response Modulation of Epigalocaten-In-3-Gallate in Staphylococcus aureus with Divergent Resistance Phenotypes

2023Journal article Open access
Simple item page
dc.contributor.authorMira, AR
dc.contributor.authorZeferino, AS
dc.contributor.authorInácio, R
dc.contributor.authorDelgadinho, M
dc.contributor.authorBrito, M
dc.contributor.authorCalado, CRC.
dc.contributor.authorRibeiro, E
dc.date.accessioned2023-05-22T09:55:08Z
dc.date.available2023-05-22T09:55:08Z
dc.date.issued2023
dc.description.abstractHealthcare-associated methicillin-resistant Staphylococcus aureus infections represent extremely high morbidity and mortality rates worldwide. We aimed to assess the antimicrobial potential and synergistic effect between Epigalocatenin-3-gallate (EGCG) and different antibiotics in S. aureus strains with divergent resistance phenotypes. EGCG exposure effects in epigenetic and drug resistance key modulators were also evaluated. S. aureus strains (n = 32) were isolated from infected patients in a Lisbon hospital. The identification of the S. aureus resistance phenotype was performed through automatized methods. The antibiotic synergistic assay was performed through disk diffusion according to EUCAST guidelines with co-exposure to EGCG (250, 100, 50 and 25 µg/mL). The bacteria's molecular profile was assessed through FTIR spectroscopy. The transcriptional expression of OrfX, SpdC and WalKR was performed by using qRT-PCR. FTIR-spectroscopy analysis enabled the clear discrimination of MRSA/MSSA strains and the EGCG exposure effect in the bacteria's molecular profiles. Divergent resistant phenotypes were associated with divergent transcriptional expression of the epigenetic modulator OrfX, particularly in MRSA strains, as well as the key drug response modulators SpdC and WalKR. These results clearly demonstrate that EGCG exposure alters the expression patterns of key epigenetic and drug response genes with associated divergent-resistant profiles, which supports its potential for antimicrobial treatment and/or therapeutic adjuvant against antibiotic-resistant microorganisms.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationAntibiotics (Basel) . 2023 Mar 4;12(3):519pt_PT
dc.identifier.doi10.3390/antibiotics12030519pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/4519
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)pt_PT
dc.subjectDrug resistance modulatorspt_PT
dc.subjectDrug resistance phenotypespt_PT
dc.subjectEpigallocatechin-3-gallate (EGCG)pt_PT
dc.subjectEpigenetic modulatorpt_PT
dc.subjectSynergistic effectspt_PT
dc.subjectStaphylococcus aureuspt_PT
dc.subjectHCC PAT CLINpt_PT
dc.titleEpigenetic and Drug Response Modulation of Epigalocaten-In-3-Gallate in Staphylococcus aureus with Divergent Resistance Phenotypespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue3pt_PT
oaire.citation.startPage519pt_PT
oaire.citation.titleAntibioticspt_PT
oaire.citation.volume12pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Antibiotics 2023_519.pdf
Size:
1.04 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

PAT CLIN - Artigos